Distribution and Associations of [−2]Proenzyme-Prostate Specific Antigen in Community Dwelling Black and White Men
Abstract
Purpose:
We provide cross-sectional normative data on [−2]proenzyme-prostate specific antigen from the Olmsted County Study of Urinary Symptoms and Health Status among Men, and the Flint Men's Health Study. We also describe associations with clinical urological measures and the risk of prostate cancer diagnosis.
Materials and Methods:
Measurements of [−2]proenzyme-prostate specific antigen were obtained from 420 white men from Olmsted County, Minnesota, and 328 black men from Genesee County, Michigan. Cross-sectional associations between [−2]proenzyme-prostate specific antigen and prostate enlargement/elevated prostate specific antigen were assessed. Cox proportional hazard models were used to assess associations between [−2]proenzyme-prostate specific antigen and the incident diagnosis of prostate cancer.
Results:
Baseline [−2]proenzyme-prostate specific antigen was slightly higher in black men at a median of 6.3 pg/ml (25th, 75th percentiles 4.1, 8.9) than in white men at a median of 5.6 pg/ml (25th, 75th percentiles 3.9, 7.7, respectively, p = 0.01). Baseline [−2]proenzyme-prostate specific antigen was highly predictive of biopsy confirmed prostate cancer in the Olmsted County Study cohort. Relative to men in the [−2]proenzyme-prostate specific antigen lower quartile those in the upper quartile were at almost eightfold increased risk for prostate cancer (HR 7.8, 95% CI 2.2−27.8) after adjusting for age and baseline prostate specific antigen.
Conclusions:
In these cohorts of community dwelling black and white men [−2]proenzyme-prostate specific antigen was much lower than in previous studies. These data suggest that [−2]proenzyme-prostate specific antigen may help identify prostate cancer in men with serum prostate specific antigen in an indeterminate range, although the reference ranges for white and black men may differ slightly.
References
- 1 : Cancer statistics, 2010. CA Cancer J Clin2010; 60: 277. Google Scholar
- 2 : Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA1993; 270: 860. Google Scholar
- 3 : Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology2000; 56: 255. Google Scholar
- 4 : A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res2000; 60: 756. Google Scholar
- 5 : Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem2004; 50: 1017. Google Scholar
- 6 : Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol2003; 170: 2181. Link, Google Scholar
- 7 : Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology2003; 62: 177. Google Scholar
- 8 : Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol2004; 171: 2239. Link, Google Scholar
- 9 : A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [−2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev2010; 19: 1193. Google Scholar
- 10 : A [−2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate2009; 69: 198. Google Scholar
- 11 : Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res2009; 15: 7316. Google Scholar
- 12 : [−2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol2010; 183: 1355. Link, Google Scholar
- 13 : The role of community-based longitudinal studies in evaluating treatment effects: Example: benign prostatic hyperplasia. Med Care1995; 33: AS26. Google Scholar
- 14 : Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch Intern Med1996; 156: 2462. Google Scholar
- 15 : The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol1993; 150: 85. Link, Google Scholar
- 16 : The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol2001; 165: 1521. Link, Google Scholar
- 17 : A population-based study of health care-seeking behavior for treatment of urinary symptoms: The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med1993; 2: 729. Google Scholar
- 18 : Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology2003; 61: 1086. Google Scholar
- 19 : Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol1999; 161: 1174. Link, Google Scholar
- 20 : Determination of prostate volume by transrectal ultrasound. J Urol1991; 145: 984. Link, Google Scholar
- 21 : Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. Urology1995; 45: 447. Google Scholar
- 22 : An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx. Urology1995; 46: 524. Google Scholar
- 23 : Additional use of [−2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer. Urology2005; 65: 926. Google Scholar
- 24 : Pre-analytical in-vitro stability of [−2]proPSA in blood and serum. Clin Biochem2010; 43: 926. Google Scholar
